IBB’s bottom ten small-cap stocks outperform
In the small-cap space, the bottom ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the bottom ten stocks of the SPDR S&P Biotechnology ETF (XBI) with a return of -0.14% and -3%, respectively, on October 6, 2015.
The above graph shows the performance of IBB and XBI’s bottom ten stocks on October 6, 2015. On a trailing five-day basis, IBB outperformed XBI with a return of 9.1% compared to XBI’s return of 3.7%.
Immunomedics and Acelrx Pharmaceuticals outperform
Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. On October 6, 2015, ~1.1 million shares were traded. The stock closed at $2.08. It was trading above the 20-day and 50-day moving averages. However, it was below the 100-day moving averages.
Acelrx (ACRX) rose by 4.2% on October 6, 2015. The stock rose due to the news of the initiation of the ARX-04 Phase 3 study. According to the press release, “ACRX announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The primary efficacy endpoint is the summed pain intensity difference (SPID) over 1-hour (SPID1). Safety endpoints, such as adverse events and vital signs will also be assessed, as will the patients’ and healthcare providers’ satisfaction with the method of pain control. The study is expected to be completed in early 2016.” Acelrx closed at $3.48. It was trading below the 20-day, 50-day, and 100-day moving averages.
Investors can also invest indirectly in these stocks through IBB. It holds stocks like Acadia Pharmaceuticals (ACAD), Dyax (DYAX) and Kite Pharmaceuticals (KITE). They had returns of -6.1%, 3.4%, and 1.6% on October 6, 2015.